Medication burden reduction and early clinical benefit through aripiprazole once monthly in schizophrenia patients with polypharmacy

• Published in: Progress in neuro-psychopharmacology & biological psychiatry Vol. 135; p. 111115
• Main Authors: Moon, Jiwan, Yang, Hyeryun, Jung, Sra, Jung, Soo Bong, Chang, Jhin-Goo, Kim, Won-Hyoung, Lee, Sang Min, Kim, Jangrae, Bang, Minji, Kim, Min-Kyoung, Shin, Dong-Won, Lee, Mi Yeon, Moon, Suhyeon, Kim, Eun Soo, Cho, Sung Joon
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 20-12-2024
• Subjects: Antipsychotics; Functional improvement; Long-acting injectable; Polypharmacy; Schizophrenia; DSM-5; AE; Schizophrenia; Long-acting injectable; Functional improvement; GAF; Antipsychotics; SD; Polypharmacy; CPE; PANSS; GCI-S; AOM
• DOI: 10.1016/j.pnpbp.2024.111115
• EISSN: 1878-4216
• ISSN: 0278-5846; 1878-4216

Antipsychotic polypharmacy is commonly used in clinical settings, with a growing trend in using long-acting injections to mitigate many side effects of polypharmacy. A previous study demonstrated that long-acting aripiprazole once-monthly (AOM) injection increased treatment adherence, restored functionality, and improved symptoms. However, there is insufficient evidence to demonstrate the therapeutic effects of AOM in polypharmacy practice. This observational study aimed to investigate the real-world clinical benefits and effectiveness of AOM by assessing changes in drug dosage, the number of drugs, clinical functioning, psychotic symptoms, and the duration of drug efficacy.
Study participants were recruited from eight study sites, with the baseline visit marking the initiation of drug treatment. Clinical and demographic data were collected from medical records at screening, baseline, and months 1, 3, 6, 9, and 12. Over 12 months, we analyzed changes in drug dosage, the number of drugs, and scores of the Positive and Negative Syndrome Scale-6 (PANSS-6), Global Assessment of Functioning (GAF), and Clinical Global Impression-Severity (CGIS).
Data from 139 participants were analyzed. Total 12-month antipsychotic doses calculated in chlorpromazine equivalents (CPE) were reduced by 32.6%. A comparison of total monthly antipsychotic doses in CPE between the first and last months showed a 24.6% reduction in the dose. Additionally, the quantity of benzodiazepine tablets/capsules, total benzodiazepine doses calculated in lorazepam equivalents, and quantity of tablets/capsules of mood stabilizers, anticholinergics, and beta blockers were significantly reduced. GAF scores increased by 14.1% over 12 months, and PANSS-6 total scores reduced by 17.3% over 12 months, with significant differences observed from month 1 and baseline, respectively. The scores steadily improved until month 9 compared to those of the previous months, continuing to improve through month 12. The CGI-S score reduced by 14.3% over 12 months, showing a significant decrease from month 1 and a steady improvement until month 6, maintaining this improvement until month 12.
In conclusion, this study demonstrated the early effectiveness of AOM in treating Korean patients with schizophrenia on polypharmacy. AOM improved function and clinical symptoms in patients with schizophrenia from treatment onset and caused a decrease in the quantity and dosage of drugs taken by the patients.
•AOM decreases patients' total antipsychotic drug intake.•AOM efficacy is evident from treatment onset and symptoms improve until month 9.•AOM improves function and symptoms in schizophrenia that lasts till month 12.